
IDEXX Laboratories (IDXX) Stock Forecast & Price Target
IDEXX Laboratories (IDXX) Analyst Ratings
Bulls say
IDEXX Laboratories has demonstrated exceptional customer retention rates at approximately 97%, enhancing the predictability of its revenue and earnings streams. The company has experienced a robust organic consumables recurring revenue growth, achieving a compound annual growth rate (CAGR) of around 16% from 2016 to 2022. Additionally, the increased adoption of IDEXX’s comprehensive product suite leads to substantial revenue growth, with customers utilizing the total offerings generating 3.5 times higher growth across all testing categories.
Bears say
IDEXX Laboratories is facing a negative outlook due to declining clinical vet visits, which fell by 1.7% year-over-year in Q4'25, indicating a persistent downward trend in the pet healthcare market. Projections for 2026 suggest an additional decline of 200 basis points in pet visits, primarily driven by economic challenges faced by lower-income pet owners. This weakening demand for veterinary services could adversely impact the adoption of IDEXX's diagnostic products and services, ultimately affecting the company's revenue growth and market position.
This aggregate rating is based on analysts' research of IDEXX Laboratories and is not a guaranteed prediction by Public.com or investment advice.
IDEXX Laboratories (IDXX) Analyst Forecast & Price Prediction
Start investing in IDEXX Laboratories (IDXX)
Order type
Buy in
Order amount
Est. shares
0 shares